Abstract Details

Title Effect of Selumetinib Treatment on Long-term Prescription Pain Medication Utilization in Adults: A Retrospective Study of a U.S. Claims Database

Topic Neuro-oncology

Presentation(s) S13 - Neuro-oncology: Advances in Diagnosis and Treatments (2:00 PM-2:12 PM)

Poster/Presentation
Number 006

Objective This retrospective claims analysis assessed the impact of selumetinib on prescription pain medication utilization (PPMU) in adults over a 3-year period.

Background Selumetinib (ARRY-142886, AZD6244), an oral inhibitor of mitogen-activated protein kinases 1 and 2, reduces plexiform neurofibroma size in patients with Neurofibromatosis Type 1. A real-world analysis showed consistent reductions in PPMU over 3 years in pediatric patients taking selumetinib. To date there are no real-world data on the impact of selumetinib on PPMU in adults.

Design/Methods Adults taking selumetinib were identified via a US claims database. Inclusion criteria were ≥3 selumetinib prescriptions (April 1, 2020−June 30, 2025), aged >21 years at selumetinib initiation, and ≥12 months of continuous enrollment and claim activity before and after the first selumetinib prescription. Follow-up was from selumetinib initiation (baseline) through the duration of treatment with selumetinib.

Results A total of 160 patients were included in the analysis (mean [standard deviation] age: 38.3 [13.0] years; female: 55%). PPMU steadily increased from 47% (n=68/144) 12 months prior to selumetinib initiation to 57% (n=91/160) at baseline. Post-selumetinib initiation, PPMU steadily reduced to 48% (n=41/86) at 1 year and 29% (n=7/24) at 3 years, representing around a two-fold reduction in PPMU. Gabapentin use declined from 29% at baseline to 13% at 3 years, and opioid use decreased from 14% at baseline to 8% at 3 years. An age- and sex-adjusted analysis using a generalized estimating equation model compared pre-selumetinib PPMU with post-selumetinib PPMU over 3 years, demonstrating a statistically significant relationship between duration of selumetinib treatment and reduced PPMU; for each year patients took selumetinib, probability of PPMU reduced by 19.5% (odds ratio 0.947 per 3 months; p=0.003).

Conclusions Consistent, lasting reductions in prescription pain medication utilization were observed over 3 years in adults taking selumetinib. These real-world findings support clinical trial evidence of the impact of selumetinib on pain.

Authors/Disclosures
Justin T. Jordan, MD, MPH, FAAN (University of Texas Southwestern Medical Center) PRESENTER	Dr. Jordan has received personal compensation for serving as an employee of City of Beverly. An immediate family member of Dr. Jordan has received personal compensation for serving as an employee of Genesis HR Solutions. An immediate family member of Dr. Jordan has received personal compensation for serving as an employee of Children's Hospital. Dr. Jordan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Shepherd Therapeutics. Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Springworks Therapeutics. Dr. Jordan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AstraZeneca. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Continental Casualty Company. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for HennLesperance. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Rhoades McKee. Dr. Jordan has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Wheeler Trigg O'Donnell. Dr. Jordan has or had stock in Navio Theragnostics. An immediate family member of Dr. Jordan has or had stock in OldGate.Dr. Jordan has or had stock in Shepherd Therapeutics.Dr. Jordan has or had stock in Khora TX. The institution of Dr. Jordan has received research support from NIH. The institution of Dr. Jordan has received research support from Department of Defense. The institution of Dr. Jordan has received research support from PCORI. Dr. Jordan has received publishing royalties from a publication relating to health care. Dr. Jordan has received publishing royalties from a publication relating to health care.
Genevieve Lyons, MSc	Mrs. Lyons has received personal compensation for serving as an employee of Alexion, AstraZeneca Rare Disease.
Theresa A. Dettling, BSN, JD, MPH, MS	Ms. Dettling has received personal compensation for serving as an employee of Alexion, AstraZeneca Rare Disease. Ms. Dettling has stock in Alexion, AstraZeneca Rare Disease.
Alyssa Bowling, PharmD	Ms. Bowling has received personal compensation for serving as an employee of AstraZeneca Rare Disease. Ms. Bowling has stock in AstraZeneca Rare Disease.
Ashwin Anand, MPH	Mr. Anand has nothing to disclose.
Mike Sicilia	Mr. Sicilia has received personal compensation for serving as an employee of Forian, Inc.
Julia Meade, MD	Dr. Meade has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Meade has received personal compensation in the range of $0-$499 for serving as a Consultant for Adivo Associates.

��ɫ��

��ɫ��